Here are the S-1 registration statements from Aptevo Therapeutics Inc (APVO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow APVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APVO filings page.
Aptevo Therapeutics Inc. (APVO) filed a Form S-1 to register for resale up to 6,444,858 shares of Common Stock issuable upon exercise of outstanding pre-funded warrants, common warrants and inducement warrants held by selling stockholders. These are secondary sales; Aptevo states it will not receive any proceeds from the resale of these shares.
The registered shares comprise up to 861,708 Pre-Funded Warrant Shares, 4,308,540 Common Warrant Shares and 1,274,610 Inducement Warrant Shares. Common stock outstanding was 1,810,215 shares as of August 21, 2026, and this figure is unchanged immediately after the offering, excluding the Resale Shares. APVO trades on Nasdaq Capital Market, where the stock last closed at $2.76 per share on August 20, 2026.
Aptevo is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with two clinical candidates (mipletamig for AML and ALG.APV-527 for solid tumors) and multiple preclinical bispecific and multi-specific antibody programs. The company highlights prior equity financings, a collaboration with Niowave in radioligand oncology, and notes continued eligibility as a smaller reporting company.
Aptevo Therapeutics is registering up to 7,075,471 shares of common stock for resale by YA II PN, Ltd. under a standby equity purchase agreement. These shares will be issued to YA over time as Aptevo sells stock to it under a $60.0 million commitment, with purchase prices set at 96% of the lowest of three daily volume-weighted average prices in each pricing period. Aptevo will not receive proceeds from YA’s resale of the registered shares, but may raise capital from its direct sales to YA during a commitment period running to January 8, 2029, subject to ownership and exchange caps. As of September 30, 2025, Aptevo had 767,164 shares outstanding, so full issuance of all 7,075,471 shares reserved for this facility would represent a very large potential increase in its share count.